From: Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia
Date | 4/8/20 | 4/25/20 | 5/7/20 | 5/11/20 | 5/14/20 | 6/8/20 | 6/18/20 | 6/25/20 | 6/28/20 |
---|---|---|---|---|---|---|---|---|---|
SARS-CoV-2 PCR | Positive | Positive | Negative | Negative | Positive | Positive | |||
COVID-19 antibodies | Positive (1:80) | Positive (1:960) | Negative | ||||||
COVID-19 symptoms | Fever, cough, abdominal pain, nausea, vomiting No oxygen requirement | Fever, acute respiratory distress requiring high-flow nasal cannula | |||||||
White blood cell count (× 103/uL) | 3.5 | 11.7 | 5.0 | 10.6 | 3.5 | 0.3 | 4.6 | ||
Absolute lymphocyte count (× 103/uL) | 1.9 | 1.4 | 1.6 | 2.6 | 0.2 | 0.1 | 0.1 | ||
C-reactive protein (mg/L) | 168.1 | 9.2 | 314.3 | ||||||
Erythrocyte sedimentation rate (mm/h) | > 145 | ||||||||
Ferritin (ng/mL) | 4569 | 3662 | > 33,511 | ||||||
Interleukin 6 (pg/mL) | 93.4 | 139.0 | |||||||
Fibrinogen (mg/dL) | 603 | 567 | 710 | ||||||
D-dimer (μg/mL FEU) | 0.83 | 0.39 | 3.54 | ||||||
CT chest findings | Moderate, bilateral, scattered ground-glass opacities | Extensive, diffuse ground-glass opacities including previously unaffected sites | |||||||
Leukemia treatment | Rituximab Cytarabine Dasatinib |